Hemostemix (CVE:HEM) Trading Up 31% – What’s Next?

Hemostemix Inc. (CVE:HEM)’s stock price shot up 31% during trading on Thursday . The company traded as high as C$0.24 and last traded at C$0.19. 727,200 shares changed hands during mid-day trading, an increase of 59% from the average session volume of 456,000 shares. The stock had previously closed at C$0.15.

Hemostemix Stock Up 31.0 %

The stock has a market cap of C$16.55 million, a price-to-earnings ratio of -9.50 and a beta of 0.20. The company has a 50 day simple moving average of C$0.09 and a 200-day simple moving average of C$0.07.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.